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α2-Adrenoceptor-activation lowers central sympathetic output, peripheral, vesicular norep-
inephrine release, epinephrine secretion, and modulates vascular tension. We previously
demonstrated that α2-adrenoceptor-mediated inhibition of basal norepinephrine release
was not reflected in plasma unless re-uptake through the norepinephrine transporter (NET)
was blocked. Tyramine activates reverse norepinephrine transport through NET. Here we
tested the hypothesis that tyramine, by engaging NET in release, also blocks re-uptake,
and therefore allows manipulation of pre-junctional α2-adrenoceptors to directly regulate
norepinephrine overflow to plasma. We compared in anesthetized spontaneously hyper-
tensive rats (SHRs) and normotensive controls (WKYs), the effect of α2-adrenoreceptor
antagonist (L-659,066) and/or agonist (clonidine) on norepinephrine overflow and increase
in total peripheral vascular resistance (TPR) evoked by tyramine-infusion (1.26µmol/min/kg,
15 min) and epinephrine secretion activated by the surgical stress. TPR was computed as
blood pressure divided by cardiac output, recorded as ascending aortic flow. Plasma cate-
cholamine concentrations after tyramine were higher in SHRs than WKYs. Pre-treatment
with L-659,066 increased the catecholamine concentrations in WKYs, but only if combined
with clonidine in SHRs. Clonidine alone reduced tyramine-induced norepinephrine over-
flow in SHRs, and epinephrine in both strains. Tyramine-induced increase in TPR was not
different after clonidine, eliminated after L-659,066 and L-659,066+ clonidine in WKYs, but
only after L-659,066+ clonidine in SHRs. We conclude that tyramine-infusion does allow
presynaptic regulation of vesicular release to be accurately assessed by measuring dif-
ferences in plasma norepinephrine concentration. Our results indicate that presynaptic
α2-adrenoceptor regulation of norepinephrine release from nerve vesicles and epinephrine
secretion is dysfunctional in SHRs, but can be restored by clonidine.
Keywords: α2-adrenoceptors, hypertension, sympathetic nervous system, norepinephrine, epinephrine, release
control, total peripheral vascular resistance
INTRODUCTION
Through their ability to inhibit norepinephrine release, the α2-
adrenoceptors (AR) represent a last line of defense against sym-
pathetic hyperactivity. This is also true for the release of cate-
cholamines from the adrenal medulla. The level of adrenergic
activity is often assessed by the plasma concentration of cate-
cholamines. In fact, epinephrine is directly released into plasma
when the adrenal medulla is stimulated, therefore plasma epi-
nephrine concentration reflects release. However, norepinephrine
from sympathetic nerve endings is released into the synapse,
where it activates postsynaptic α1AR, α2AR, and/or βAR, but
some norepinephrine escapes these receptors and may modu-
late transmitter release by activating presynaptic AR. The signal
is terminated by the return of norepinephrine from the synapse
into the nerve varicosities by re-uptake through the norepineph-
rine transporter (NET; Figure 1). Only a fraction of the released
norepinephrine therefore enters the circulation, and the plasma
norepinephrine concentration does not directly reflect the amount
released. In recent studies on anesthetized normotensive (WKY)
rats under resting conditions, we demonstrated that inhibition
of either NET or α2AR did not alter the plasma norepinephrine
concentration. This observation indicated that one mechanism
substituted for the other in limiting the concentration of norep-
inephrine in the synapse, and, hence, overflow to plasma (Berg
et al., 2012). However, if we injected the α2AR antagonist after
prior administration of the NET inhibitor desipramine, the plasma
norepinephrine concentration increased. Therefore, presynaptic
α2AR-mediated inhibition of release was not reflected as a change
in the plasma norepinephrine concentration unless re-uptake was
blocked. By contrast, in this same study, the augmenting effect
of α2AR antagonist in desipramine-treated rats was far greater in
spontaneously hypertensive rats (SHRs) than in WKYs (Berg et al.,
2012).
The α2AR are divided into three subtypes, i.e., α2A, α2B, and
α2C, and deletion of the α2AAR-gene created a hypertensive mouse
with high plasma norepinephrine levels (Makaritsis et al., 1999).
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FIGURE 1 | Norepinephrine release in the sympathetic synapse. Vesicular
release is stimulated by Ca2+ and inhibited by α2AR. The re-uptake of
norepinephrine through NET can be reversed to release by tyramine. Then
NET will be engaged in release and re-uptake is hampered, and overflow to
plasma is increased. However, vesicular norepinephrine release is not directly
influenced by this process, and will still be subjected to presynaptic control by
the α2AR or other presynaptic receptors. Clonidine will lower the sympathetic
tone through a central action, as well as stimulate presynaptic and
postsynaptic α2AR. L-659,066, which does not cross the blood-brain barrier,
will inhibit the peripheral pre- and postsynaptic α2AR. In the VSMC, L-659,066
will allow βAR-Gs-signaling to dominate tension control when norepinephrine
release is stimulated. Blunted arrows indicate inhibition.
Elevated sympathetic tone plays an important role in initiating
and sustaining hypertension in SHRs as in essential hypertension
in human (Esler, 2010), and there is evidence that a failing α2AR
inhibition of catecholamine release may contribute to the high
sympathetic activity. Thus, impaired α2AR-mediated inhibition
of release has been described in both the central nervous system
(CNS) and in peripheral nerves of SHRs (Yamada et al., 1989;
Remie et al., 1992; Reja et al., 2002; Zugck et al., 2003). Indeed, we
demonstrated impaired CNS α2AR inhibition by using clonidine,
which easily penetrates the blood-brain barrier. In the presence of
the α2AR antagonist L-659,066, which does not cross the blood-
brain barrier, clonidine normalized the elevated mean arterial
blood pressure (MBP), heart rate (HR), and total peripheral vas-
cular resistance (TPR) and reduced norepinephrine overflow to
plasma in SHRs (Berg et al., 2012). However, in the resting con-
dition, we did not detect a failing α2AR control of peripheral
catecholamine release in SHRs (Berg et al., 2012).
α2AR on vascular smooth muscle cells (VSMC) induce vaso-
constriction (Philipp et al., 2002), whereas endothelial α2AAR
may activate nitric oxide (NO)-dependent vasodilatation (Sha-
faroudi et al., 2005). Vasoconstriction evoked by stimulation of
α2AR on VSMC has been shown to be impaired in SHRs (Feres
et al., 1998), and a vasodilatory α2AR-component, which opposed
a sympathetic TPR-response in WKYs, was not observed in SHRs
(Berg and Jensen, 2011). Activation of inhibitory G-proteins
(Gi) and inhibition of adenylyl cyclase is one mechanism by
which α2AR may activate vasoconstriction, counter-balanced by
the stimulatory effect of βAR on adenylyl cyclase (Figure 1).
However, the moderating effect of α2AR antagonist on a
phenylephrine-induced, α1AR-mediated vasoconstriction did not
differ in the two strains (Berg et al., 2012). This may be different
when endogenous norepinephrine is released into the synapse, and
can activate not only α1- but also α2- and βAR. In addition, other
signaling substances, such as neuropeptide Y and ATP, co-released
with norepinephrine, may influence the response (Burnstock and
Verkhratsky, 2010).
In order to demonstrate the full effect of α2AR stimulation on
catecholamine release and TPR, in vivo experiments are required
involving inhibition of re-uptake through NET and concomitant
activation of endogenous norepinephrine release. Norepinephrine
release can be activated by tyramine, which stimulates periph-
eral release by reverse transport through NET (Mandela and
Ordway, 2006; Berg et al., 2010), and unlike vesicular release,
NET-mediated release is not under presynaptic control (Starke,
2001). However, since tyramine will engage NET in release, we
hypothesized that re-uptake is also prevented (Figure 1), and
presynaptic modulation of vesicular release reflected as differ-
ences in the concomitant tyramine-stimulated norepinephrine
overflow to plasma. This hypothesis was tested in the present
study. We recorded BP and cardiac output in order to establish
how α2AR activation influenced TPR during tyramine-infusion.
Because we hypothesized that the function of α2AR is different in
WKYs and SHRs, we carried out similar experiments on the two
strains.
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MATERIALS AND METHODS
EXPERIMENTAL PROCEDURE
All experiments were approved by the institutional review commit-
tee, and conducted in accordance with the National Institutes of
Health (NIH) Guide for the Care and Use of Laboratory Animals.
Twelve- to fourteen-weeks-old, male WKYs (n= 57, 289± 5 g
body weight) and SHRs (Okamoto, SHR/NHsd strain, n= 58,
284± 4 g body weight) on 12/12 h light/dark cycles were allowed
conventional rat chow diet (0.7% NaCl) and water ad lib until
the time of the experiment. The rats were anesthetized with pen-
tobarbiturate (70-75 mg/kg, i.p.). As previously described (Berg
et al., 2010), the rats were instrumented with a catheter in the
femoral artery to monitor systolic (SBP) and diastolic (DBP) BP,
and a flow probe on the ascending aorta to register CO and HR.
MBP (SBP-DBP/3+DBP), TPR (MBP/CO), and stroke volume
(SV=CO/HR) were calculated. T F (time from onset of flow to
maximum rise in flow, derived from high resolution aorta flow
data, i.e., 5000 points/2 s) was used to indicate changes in inotropy
(Berg et al., 2010). The rats were on a positive pressure ventila-
tor throughout the experiment, ventilated with air. Measurements
of blood gas parameters demonstrated adequate ventilation in
both strains (Berg, 2002, 2003). Body temperature was main-
tained at 37–38˚C by external heating, guided by a thermo sensor
inserted inguinally into the abdominal cavity. After completion
of the surgery, the arterial catheter was flushed with 0.15 ml PBS
(0.01 M Na-phosphate, 0.14 M NaCl, pH 7.4) containing 500 IU
heparin/ml. Drugs were dissolved in PBS, and, unless otherwise
indicated, administered as bolus injections (0.6–1 ml/kg) through
a catheter in the femoral vein, flushed with 0.1 ml PBS.
EXPERIMENTAL DESIGN
To stimulate endogenous release of norepinephrine, all rats
were infused for 15 min with tyramine (1.26µmol/min/kg,
217µl/min/kg, Berg, 2005). The control group (PBS+ tyramine)
was injected with PBS 10 min prior to the tyramine-infusion.
To identify responses caused by the tyramine-induced reverse
transport through NET, rats were injected i.p. with the NET
inhibitor desipramine hydrochloride (44µmol/kg) 5 h prior to
the experiment (Miralles et al., 2002; Berg et al., 2012), and
pre-treated with PBS 10 min before tyramine during the exper-
iment (desipramine+PBS+ tyramine). To test if the tyramine-
evoked rise in BP elicited baroreceptor activation and reflex
vagal inhibition of HR, another group was pre-treated with the
muscarinic receptor antagonist atropine sulfate (2.9µmol, Berg,
2002) 20 min before tyramine (atropine+ tyramine). To ana-
lyze the influence of α2AR, rats were pre-treated with the non-
selective α2AR antagonist L-659,066, which does not penetrate
the blood-brain barrier (Clineschmidt et al., 1988; 4.4µmol/kg,
10 min before tyramine, Berg et al., 2012; L-659,066+ tyramine),
or with the non-selective, α2AR-agonist clonidine, which easily
penetrates the blood-brain barrier (151 nmol/kg, 15 min prior
to tyramine, Berg et al., 2012). Clonidine was injected 10 min
after a sham-injection with PBS (PBS+ clonidine+ tyramine)
or L-659,066 as above (L-659,066+ clonidine+ tyramine) to
differentiate between involvement of CNS and peripheral
α2AR. In a time-control group, the rats were pre-treated with
PBS and subsequently infused with PBS instead of tyramine
(PBS+PBS). The number of rats per group is shown in
Table 1.
Table 1 | Cardiovascular baselines prior to tyramine and, in parenthesis, the response to pre-treatment.
Pre-treatment WKY SHR
N MBP
(mm Hg)
HR
(beats/min)
CO
(ml/min)
TPR (mm Hg/
ml/min)
N MBP
(mm Hg)
HR
(beats/min)
CO
(ml/min)
TPR (mm Hg/
ml/min)
PBS (control) 17 77±4
(3±3)
338±8
(−4±7)
36±2
(4±1)
2.2±0.2
(−0.2±0.1)
15 91±4*
(−6±8)
368±8*
(−20±7)
17±1*
(1±1)
5.4±0.3*
(−0.6±0.2)
PBS after desipramine 6 50±2
(−2±3)
310±14
(−4±13)
28±3
(0±1)
1.9±0.2
(−0.1±0.1)
6 63±7†
(−8±3)
350±29
(−8±5)
13±2
(−1±0)
4.8±0.3
(−0.2±0.3)
Atropine sulfate 6 63±6
(−8±9)
324±11
(−16±13)
34±2
(4±3)
1.9±0.2
(−0.5±0.2)
6 99±7
(−11±15)
356±5
(−24±8)
19±1
(2±2)
5.1±0.3
(−1.3±0.5)
PBS+ clonidine 7 64±2
(−4±5)
316±7
(−35±7)†
41±3
(12±1)†
1.6±0.1†
(−0.8±0.1)†
10 56±4†
(−42±7)†
318±9†
(−113±13)†
16±1
(−1±1)
3.5±0.2†
(−2.2±0.4)†
L-659,066 6 50±3†
(−16±2)†
322±11
(−25±6)
32±3
(1±1)
1.6±0.1
(−0.6±0.0)†
7 76±5
(−12±3)
400±14
(−23±10)
19±2
(1±1)
4.3±0.4
(−0.8±0.2)
L-659,066+ clonidine 8 50±2†
(−24±2)†§
319±7
(−48±8)†
32±2
(3±1)
1.6±0.1†
(−1.0±0.1)†§
7 44±2†‡§
(−53±7)†§
334±13§
(−92±15)†§
16±1
(−4±1)§
2.8±0.1†‡§
(−2.3±0.4)†§
Since desipramine was administered before cardiovascular recording was started, its effects were measured by the differences in baselines compared to that in
the corresponding PBS-control group. After one-way ANOVA revealed the presence of group differences within each strain (P≤0.05), these were located as indi-
cated after comparisons between PBS-control and experimental groups ( †), between groups given L-659,066+ clonidine and PBS+ clonidine ( ‡), and between the
L-659,066+ clonidine and L-659066-treated groups ( §). Comparison between WKY and SHR was done for the baselines in the PBS+ tyramine control groups only
(∗). Baselines in the PBS+PBS time-control group did not differ from that in the corresponding PBS+ tyramine control group (data not shown). *P≤0.05. †, ‡,
§ – P≤0.0071.
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MEASUREMENT OF PLASMA CATECHOLAMINES
Blood was sampled from the femoral artery catheter immediately
after the 15-min tyramine-observation period but without discon-
tinuing the infusion of tyramine. About 1.5 ml blood was collected
into tubes containing 40µl 0.2 M glutathione and 0.2 M EGTA.
Plasma was stored at−80˚C until norepinephrine and epinephrine
concentrations were determined with an HPLC-electrochemical
detection method (Jensen et al., 2005).
DRUGS
L-659,066 was a kind gift from Merck, Sharp, and Dohme Labs,
Rahway, NJ, USA. The remaining drugs were from Sigma Chemical
Co., St. Louis, MO, USA.
STATISTICAL ANALYSES
The results are presented as mean values± SEM. Data for MBP,
HR, CO, SV, and TPR were averaged every minute. The mean
of T F (indicating changes in inotropy) from five 2-s-period col-
lections of high resolution data was used to determine T F at
specific times. The cardiovascular response-curves to tyramine
were analyzed using Repeated Measures Analyses of Variance and
Covariance, first as over-all tests within each strain, and subse-
quently for each group separately or between groups. Significant
responses and group differences were subsequently located using
one- and two-sample Student’s t -tests, respectively, at specific
times. Effects of pre-treatment, differences in cardiovascular base-
lines, and∆T F were first evaluated by one-way ANOVA including
all groups within each strain separately, followed by post hoc analy-
ses using two-sample Student’s t -tests to locate differences between
groups. Significant changes in T F (∆T F) were detected with one-
sample Student’s t -tests. Differences in cardiovascular baselines
between WKY and SHR were tested in the PBS+ tyramine con-
trol groups only using two-sample Student’s t -tests. Differences
in the plasma catecholamine concentrations across groups and
strain were first evaluated by two-way ANOVA, followed by two-
sample Student’s t -tests to locate group differences. In the presence
of out-liers, two-sample Student’s t -tests were substituted with
non-parametric Kruskal–Wallis tests. For all tests and at each step,
testing proceeded only when the presence of significant differ-
ences and/or interactions were indicated. The P-value was for all
tests and each step adjusted according to Bonferroni, except for
the catecholamine and T F data, where P ≤ 0.05 was considered
significant.
RESULTS
CARDIOVASCULAR BASELINES AND THE RESPONSE TO
PRE-TREATMENT
MBP, HR, and TPR baselines were higher in SHRs than in WKYs,
whereas CO was less (Table 1). The NET inhibitor desipramine
reduced MBP in SHRs, but otherwise had no significant effect
on baselines (Tables 1 and 2). Changes in baselines were also not
detected after pre-treatment with atropine (Tables 1 and 2). As
previously described (Berg et al., 2012), clonidine-induced first a
peripheral, vascular response, i.e., a transient increase in MBP and
TPR, which was reduced by L-659,066 in WKYs and eliminated by
L-659,066 in SHRs (data not shown). The subsequent clonidine-
induced fall in MBP, TPR, and HR was greater in SHRs than in
WKYs also in the presence of L-659,066 (P ≤ 0.001), and MBP,
HR, and TPR in SHRs after L-659,066+ clonidine no longer dif-
fered from that in the WKY controls (P =NS; Table 1). L-659,066
alone reduced MBP and TPR baselines in WKYs, but had no sig-
nificant effect in SHRs. Clonidine and L-659,066 had no effect on
inotropy in WKYs (Table 2). However, clonidine had a negative
inotropic effect (prolonged T F) and L-659,066 a minor, positive
inotropic effect in SHRs (Table 2).
THE RESPONSE TO TYRAMINE
Norepinephrine overflow to plasma
Tyramine greatly increased the plasma concentration of norep-
inephrine in both strains (P < 0.001, PBS+ tyramine controls
compared to PBS+PBS time-controls), and to a greater extent
in SHRs than in WKYs (Table 3). This tyramine-induced over-
flow was abolished by pre-treatment with the NET inhibitor
desipramine in both strains (P =NS compared to the PBS+PBS
time-controls).
The tyramine-induced norepinephrine overflow in WKYs was
not different after pre-treatment with clonidine, but was increased
after L-659,066. The latter increase was eliminated by additional
pre-treatment with clonidine (P = 0.049). The opposite pattern
was observed in SHRs, where tyramine-stimulated norepineph-
rine overflow was not different after pre-treatment with L-659,066,
but was reduced after clonidine (P = 0.006), in fact to the same
Table 2 | Changes inT F as an indication of changes in inotropy in response to pre-treatment and tyramine.
Pre-treatment WKY SHR
∆T F (%) Pre-treatment ∆T F (%)Tyramine ∆T F (%) Pre-treatment ∆T F (%)Tyramine
PBS (control) 4±2 −30±1* 4±2 −31±2*
PBS after desipramine 5±2 0±2† 5±3 −11±5†
Atropine sulfate −1±1 −28±1* 3±2 −38±2*†
PBS+ clonidine 2±3 −36±3* 16±6*† −38±4*†
L-659,066 2±6 −35±4* −6±4† −34±1*
L-659,066+ clonidine 11±8 −37±3*† 12±11 −30±5*
% Change in TF (∆TF) indicated differences in inotropy, i.e., a prolongation of TF indicated a negative inotropic effect. ∗ – significant changes in ∆TF. † – significant
differences between the control and the experimental groups. ∗, † – P≤0.05.
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Table 3 |The plasma concentration of norepinephrine and epinephrine at the end of the tyramine-infusion period.
Treatment WKY SHR
Norepinephrine (nM) Epinephrine (nM) Norepinephrine (nM) Epinephrine (nM)
PBS+PBS (time−control) 0.6±0.1 7.3±1.3 1.4±0.1* 11.9±1.7
PBS+ tyramine (control) 27.3±1.1† 2.9±0.5† 34.1±3.6†* 11.2±2.1*
Desipramine+PBS+ tyramine 0.9±0.1‡ 0.4±0.1‡ 3.1±1.0‡ 2.2±0.7‡
PBS+ clonidine+ tyramine 27.3±1.6 0.8±0.1‡ 26.0±1.7‡ 2.5±1.5‡
L−659,066+ tyramine 35.7±2.9‡ 10.2±3.1‡ 38.8±5.1 13.6±4.0
L−659,066+ clonidine+ tyramine 26.9±1.9a 9.0±4.1‡§ 42.1±5.8§ 22.0±10.2§
Plasma was collected at the end of the tyramine-infusion period. Two-way ANOVA demonstrated the presence of significant differences between groups and
strain and for group differences across strain (P≤0.019). Comparisons were subsequently made between SHRs and WKYs in the PBS+PBS time-control and
PBS+ tyramine control groups (∗), between corresponding PBS+PBS time-control and PBS+ tyramine control groups ( †), between corresponding PBS+ tyramine
control and experimental groups ( ‡), between groups pre-treated with PBS+ clonidine+ tyramine and L-659,066+ clonidine+ tyramine ( §), and groups pre-treated
with L-659,066+ tyramine and L−659,066+ clonidine+ tyramine (a). Significant differences were detected as indicated. Plasma catecholamine concentrations were
not recorded in the atropine-treated rats. ∗, †, ‡, §, a – P≤0.05.
level as that in the WKY tyramine controls (P =NS). This reduc-
tion was eliminated when L-659,066 was given prior to clonidine,
and the plasma norepinephrine concentration in the SHR L-
659,066+ clonidine+ tyramine group was not different from that
in the SHR PBS+ tyramine controls. Since L-659,066 does not
cross the blood-brain barrier, these results showed that inhibition
of peripheral α2AR enhanced tyramine-induced overflow of nor-
epinephrine in WKYs, whereas the elevated overflow in SHRs was
not controlled by peripheral α2AR.
The secretion of epinephrine
We have previously shown that the experiment itself induced
some secretion of epinephrine, since the plasma concentration
at the end of the experiment in time-controls given PBS+PBS
was higher than in rats where blood was collected immediately
after femoral artery catheterization and with no other surgery
(Berg et al., 2012; Table 3). This secretion was reduced by tyra-
mine in WKYs (P = 0.004, PBS+ tyramine controls compared to
PBS+PBS time-controls), but not in SHRs. The plasma epineph-
rine concentration was therefore higher in SHRs than in WKYs
in the PBS+ tyramine controls, but not in the PBS+PBS time-
controls. The level of circulating epinephrine was reduced after
desipramine+ tyramine in both strains.
L-659,066 increased the plasma concentration of epineph-
rine in WKYs, but not in SHRs, whereas clonidine clearly
reduced the concentration of epinephrine in both strains. This
decrease was abolished by prior administration of L-659,066 (L-
659,066+ clonidine+ tyramine); in WKYs returned to the same
level as in the L-659,066-only group, i.e., higher than in the WKY
controls, and in SHRs, to the same elevated level as in the SHR
PBS+ tyramine controls.
The cardiovascular response
As previously documented (Berg, 2005; Berg et al., 2010),
tyramine-induced an immediate, but transient rise in TPR and a
sustained increase in MBP, CO, and HR (Figure 2). Tyramine also
reduced T F (Table 2), indicating a positive inotropic response,
but had little effect on SV (Figure 2). These responses were all
virtually eliminated by desipramine (Figure 2; Table 2), verifying
their dependence on NET-mediated norepinephrine release. The
HR-response to tyramine was not different after atropine in either
strain (Figure 2), although a minor, further decrease in T F was
observed in SHRs (Table 2).
Clonidine alone had no significant effect on the TPR-peak-
response to tyramine in either strain (Figure 3). L-659,066
eliminated the TPR-response to tyramine in WKYs (P ≤ 0.008
compared to the controls), and this reduction was not differ-
ent after additional pre-treatment with clonidine. However, in
SHRs, L-659,066 alone had no significant effect on the TPR-
response to tyramine, whereas L-659,066+ clonidine totally elim-
inated the tyramine-induced rise in TPR and even precipi-
tated a vasodilatory TPR-response (Figure 3). These changes
were paralleled by a lower tyramine-induced rise in MBP after
L-659,066 and L-659,066+ clonidine in WKYs and after L-
659,066+ clonidine in SHRs (Figure 3). The rise in CO (Figure 3)
was reduced in L-659,066- and/or clonidine-treated WKYs, and
after L-659,066 in SHRs, paralleled by a reduction in SV (not
shown). The tyramine-induced tachycardia was not different in L-
659,066 and/or clonidine-treated WKYs, but was reduced after
L-659,066 and increased after clonidine in SHRs (Figure 3).
L-659,066+ clonidine enhanced the positive inotropic effect of
tyramine, i.e., further decreased T F, in WKYs, whereas clonidine
but not L-659,066+ clonidine enhanced the response in SHRs
(Table 2).
DISCUSSION
In the present study, tyramine-induced reverse transport of nor-
epinephrine through NET increased norepinephrine overflow to
plasma with a greater effect in SHRs than in WKYs. We demon-
strated that pre-treatment with the α2AR antagonist L-659,066
enhanced this overflow in WKYs, but had no effect on the elevated
overflow in SHRs. The tyramine-activated release of norepineph-
rine induced a transient rise in TPR, which was totally abolished
by L-659,066 in WKYs but not in SHRs. These α2AR abnormalities
in SHRs were eliminated when the pre-treatment with L-659,066
was combined with clonidine.
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FIGURE 2 |The effect of the NET inhibitor desipramine and the
muscarinic antagonist atropine on the cardiovascular response to
tyramine. After curve evaluation using Repeated Measures Analyses of
Variance and Covariance (please see Materials and Methods), significant
responses (* within symbol) were detected at 3 and 15 min for ∆MBP, ∆TPR,
and ∆SV, and at 15 min for ∆CO and ∆HR, as indicated. Significant group
differences at 3 min (* in left brackets) or 15 min (* in right brackets) were
detected as indicated. Baselines prior to tyramine are shown inTable 1.
*within symbols: P ≤0.025 for ∆MBP, ∆TPR and ∆SV, and P ≤0.05 for ∆CO
and ∆HR. * in brackets: P ≤0.001.
FIGURE 3 |The changes in MBP,TPR, CO, and HR inWKYs and
SHRs during tyramine-induced norepinephrine release after
pre-treatment with the centrally active, non-selective
α2AR-agonist clonidine and the peripherally restricted α2AR
antagonist L-659,066, separately or combined. After curve
evaluation using Repeated Measures Analyses of Variance and
Covariance (please see Materials and Methods), significant responses
(* within symbol) and group differences (* in brackets) were detected
at 3 and 15 min for ∆MBP and ∆TPR, and at 15 min for ∆CO and ∆HR,
as indicated. Baselines prior to tyramine are shown inTable 1. * within
symbols and * in brackets: P ≤0.025 for ∆MBP and ∆TPR, and
P ≤0.05 for ∆CO and ∆HR.
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Unlike vesicular release, which is Ca2+-dependent, NET-
mediated norepinephrine release is not under presynaptic control
(Starke et al., 1989). Still, inhibition of peripheral α2AR increased
the tyramine-induced norepinephrine overflow to plasma in
WKYs, indicating that presynaptic α2AR modified the response.
The increase was eliminated after additional pre-treatment with
clonidine, further supporting an α2AR involvement. Tyramine
stimulates reverse transport through NET (Mandela and Ordway,
2006), as confirmed by the fact that desipramine eliminated the
tyramine-induced norepinephrine overflow. It therefore seemed
that by engaging NET in release, tyramine blocked re-uptake, and,
through that, allowed presynaptic control of release to be reflected
as differences in norepinephrine overflow to plasma (Figure 1).
The condition created by tyramine, therefore appeared to paral-
lel that created by inhibition of NET norepinephrine re-uptake
by desipramine, where α2AR-mediated inhibition of release was
detected as an increase in the plasma norepinephrine concentra-
tion in rats where endogenous norepinephrine release was not
stimulated (Berg et al., 2012). We therefore concluded that the pro-
tocol developed in the present study allow tyramine to be used as
a tool to investigate α2AR-induced modulation of norepinephrine
release.
Tyramine penetrates the blood-brain barrier poorly (Olden-
dorf, 1971), and its action will therefore be restricted to periph-
eral nerves. The same is true of L-659,066. The α2AR respon-
sible for inhibiting norepinephrine release were therefore likely
to be located on peripheral sympathetic nerve terminals. In
WKYs, α2AR-mediated inhibition of norepinephrine release dur-
ing tyramine-stimulation appeared to be fully activated, since the
plasma norepinephrine concentration was not reduced by cloni-
dine. However, α2AR inhibition of release appeared dysfunctional
in SHRs, since L-659,066 did not augment norepinephrine over-
flow in this strain. This conclusion was in agreement with that
observed by others (Remie et al., 1992; Zugck et al., 2003). The
plasma norepinephrine concentration in the SHR tyramine con-
trols was therefore higher than in WKYs, and similar to that in
WKYs pre-treated with α2AR antagonist. In SHRs, α2AR stimula-
tion with clonidine reduced the plasma norepinephrine concen-
tration and allowed L-659,066 to augment release, i.e., overflow.
However, it could not from the present experiments be concluded
if the restoring effect of clonidine on the failing α2AR control
of norepinephrine release in SHRs involved activation of periph-
eral α2AR directly or was due to the reduced central sympathetic
output following clonidine in this strain.
We have in previous experiments demonstrated that the level of
circulating epinephrine in time-controls exposed to a full exper-
iment, i.e., artificial ventilation, open chest, and flow probe on
the ascending aorta, was greater than that in rats where blood was
sampled immediately after femoral artery catheterization, without
further surgery (Berg et al., 2012). Secretion of epinephrine was
therefore induced by the trauma of the experiment, most likely
due to surgical stress and activation of the sympatho-adrenal axis.
This conclusion was compatible with the observed delay in the rise
in circulating epinephrine compared to that of norepinephrine in
tyramine-stimulated rats (Berg et al., 2010). Mechanisms that con-
trol this trauma-stimulated epinephrine secretion could therefore
be examined. Since L-659,066 increased the plasma epinephrine
concentration in WKYs but not in SHRs, α2AR auto-inhibition of
also epinephrine secretion apparently failed in SHRs. Clonidine
reduced the plasma concentration of epinephrine in both strains,
and this reduction was eliminated after additional pre-treatment
with L-659,066. Thus, α2AR-mediated inhibition of epinephrine
secretion, unlike that of norepinephrine, was not fully activated
in WKYs. Moreover, clonidine restored also the failing control of
epinephrine secretion in SHRs, similar to that of norepinephrine.
The plasma epinephrine concentration was reduced by tyra-
mine in WKYs. This suggested that epinephrine-producing cells
did not contain NET. The tyramine-induced reduction in epi-
nephrine secretion may be explained if tyramine stimulated nor-
epinephrine release in the adrenal glands, and thereby activated
α2AR on neighboring epinephrine-secreting cells. Activation of
α2AR inhibition of epinephrine release may also result from the
high norepinephrine concentration in plasma due to tyramine-
stimulated neuronal release. A similar effect was not observed in
SHRs, in agreement with an α2AR malfunction of release con-
trol in this strain. The contribution of NET located on adrenal
norepinephrine-producing cells to the plasma norepinephrine
concentration was not fully clarified in the present study. However,
preliminary studies indicated that the α2AR antagonist L-659,066
increased tyramine-stimulated norepinephrine overflow in WKYs
also after acute adrenalectomy (Berg, unpublished observations).
The epinephrine concentration was in both strains reduced
by desipramine, a tricyclic antidepressant which enters the CNS.
A similar reduction was also seen without tyramine-stimulated
norepinephrine release (Berg et al., 2012). This reduction may
in WKYs be explained by that desipramine inhibited re-uptake
in norepinephrine-secreting adrenal cells and activated close by
α2AR, which inhibited epinephrine secretion, as discussed above.
However, in SHRs, due to the elevated sympathetic tone in
this strain, this reduction may be explained by a reduced CNS
sympathetic output, since intracerebroventricular application of
desipramine reduced BP and CNS norepinephrine overflow to
plasma in rabbits (Esler et al., 1995). It is also possible that
desipramine through a central action interfered with the trauma-
induced activation of epinephrine secretion. The inhibitory effect
of desipramine on the secretion of epinephrine as well as its possi-
ble central action may explain why desipramine reduced baseline
BP in SHRs. In addition, these effects will have limiting impli-
cations for the use of desipramine to study the physiology of
catecholamine release control.
The peripheral antagonist L-659,066 induced a sustained
reduction in TPR baseline in WKYs, demonstrating the presence
of a basal α2AR-induced vasoconstrictory tone in WKY. The influ-
ence of endothelial α2AAR-activated NO-synthesis was therefore
not detected in the present study, even though NO-dependent
vasodilatation dominated the influence of α2AR stimulation in the
isolated rat aorta (Carter et al., 2002). This is probably explained by
the fact that in vivo norepinephrine is mainly released abluminally
and therefore has access more readily to receptors on the VSMC
than on the endothelium. It may be noted that basal release of nor-
epinephrine was also enhanced by L-659,066, as demonstrated in
our previous study involving desipramine, but not tyramine (Berg
et al., 2012). L-659,066 did not reduce baseline TPR in SHRs, indi-
cating a failing VSMC α2AR tone, in agreement with also a reduced
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sensitivity to the Gi-inhibitor pertussis toxin in this strain (Berg
et al., 2009). α2AR-mediated differences in catecholamine release
apparently did not influence TPR. However, differences in release
may explain the negative and positive inotropic effect of clonidine
and L-659,066, respectively.
Peripheral NET-mediated norepinephrine release was respon-
sible for the cardiovascular responses following tyramine, since
these were all virtually eliminated by desipramine. α2AR-mediated
control of TPR during tyramine-stimulation could not be further
activated in either strain, since clonidine alone did not enhance
the TPR-response to tyramine. This observation paralleled that
observed in previous experiments, where clonidine had no effect
on the TPR-response to the α1AR agonist phenylephrine (Berg
et al., 2012). The vasoconstrictory TPR-response to tyramine was
totally eliminated after pre-treatment with L-659,066 in WKYs.
This reduction, like the L-659,066-dependent fall in TPR baseline,
was likely to be explained by an increased adenylyl cyclase-induced
vasodilatation, probably activated by βAR-Gs-signaling, allowed to
dominate VSMC tension control when the α2AR-Gi pathway was
blocked (Figure 1). This assumption was supported by the fact
that βAR-blockers enhanced the tyramine-induced vasoconstric-
tion (Berg et al., 2010). Thus, in the presence of α2AR antagonist,
the TPR-response to tyramine in WKYs was low even though
plasma norepinephrine and epinephrine levels were increased,
underlining the importance of VSMC receptor interaction for
the final effect on VSMC tension. However, in SHRs, L-659,066
alone did not inhibit tyramine-induced vasoconstriction, but did
so, and even resulted in tyramine-induced vasodilatation, when
combined with clonidine. We detected no strain-related differ-
ence in the ability of L-659,066 to moderate the α1AR-mediated
vasoconstrictory response to phenylephrine (Berg et al., 2012).
We therefore concluded that similar to that seen for peripheral
catecholamine release control, VSMC α2AR were dysfunctional in
SHRs only when norepinephrine release was activated. Therefore,
the failingα2AR control of TPR in SHRs, like that of catecholamine
release, occurred as a consequence of stimulation of release.
Norepinephrine released by tyramine was likely to be the ago-
nist responsible for presynaptic α2AR release modulation, acting
in concert with numerous other agonists released from the same
or adjacent neurons, or otherwise present in the nearby intercellu-
lar space (Kubista and Boehm, 2006; Burnstock and Verkhratsky,
2010; MacArthur et al., 2011). For instance, epinephrine from the
circulation or co-released with norepinephrine from sympathetic
nerve terminals may activate presynaptic β2AR, which stimulate
release of norepinephrine (Majewski, 1983), and, in that manner,
interfere with α2AR inhibition of release. Similarly, a possible co-
release of other sympathetic nerve transmitters such as neuropep-
tide Y and ATP (Burnstock and Verkhratsky, 2010; MacArthur
et al., 2011) may also influence the impact of α2AR inhibition of
release. However, such reactions will not neutralize the observa-
tions made with the use of α2AR-selective agonist or antagonist,
but may explain why a failing α2AR inhibition of norepinephrine
and epinephrine release was observed during tyramine-stimulated
release but not in desipramine-treated SHRs without stimulation
of release (Berg et al., 2012). This conclusion was compatible with
that α2AR inhibition of epinephrine secretion was not impaired
in isolated adrenal medulla from SHRs of comparable age (Moura
et al., 2011). Also the postsynaptic effect of norepinephrine on
VSMC will be influenced by vasoactive agents co-released with
or released by norepinephrine (Burnstock and Verkhratsky, 2010;
MacArthur et al., 2011). The influence of such interacting agents
may be elucidated, one by one, in the same way as we here have
studied the contribution of the α2AR.
In the present experiments, we measured total norepinephrine
overflow and changes in total body vascular resistance. However,
a physiological, adrenergic hemodynamic response will be finely
regulated to meet situation-dependent and local demands. Still,
since tyramine-evoked a general, whole-body sympathetic activa-
tion, these gross parameters seemed relevant. Since an important
issue of our studies is to gain a better understanding of the etiol-
ogy of spontaneous hypertension, understanding the mechanisms
responsible for sympathetic hyperactivity and the rise in TPR
in SHRs, and in essential hypertension in humans is important.
The present study design offered an opportunity by which such
information may be enhanced.
The rats were connected to a positive pressure ventilator
throughout the experiment to maintain stable blood gas values,
as previously demonstrated (Berg, 2003). However, positive pres-
sure ventilation will hamper right ventricular ejection, and, hence,
reduce venous return to the right atrium, and, through that, left
heart function, leading to a reduced CO and consequently BP. We
therefore observed a reduction in MBP in SHR (from 127± 10 mm
Hg before connection to the ventilator to 98± 5 mm Hg after com-
pletion of surgery and the 10-min stabilization period, n= 17,
P = 0.012), most likely due to the low CO recorded in this strain.
A similar reduction in MBP was not observed in WKY (from
75± 5 to 74± 3 mm Hg, n= 13, P =NS). In agreement with a
weak baroreceptor reflex function in anesthetized rats (Berg et al.,
2012), the reduction in MBP baseline in SHR did not result in
a strain-related difference in the plasma catecholamine concen-
trations in time-controls exposed to ventilation and full surgical
procedure, or in rats not subjected to artificial ventilation or
surgery other than the femoral artery catheterization (Berg et al.,
2012). A strain-related difference in un-stimulated plasma norep-
inephrine overflow was also not seen when re-uptake was blocked
by desipramine. A reduction in MBP baseline was not likely to
directly influence the tyramine-induced reversed norepinephrine
transport through NET in peripheral sympathetic nerves, and,
hence, not the cardiovascular responses to tyramine. Activation of
baroreceptor reflexes did not influence the cardiovascular response
to tyramine, since this was not influenced by atropine. In addi-
tion, the cardiovascular responses to tyramine were not compared
across strain. We therefore concluded that the low MBP and CO in
SHR in the present experimental set-up were not likely to influence
our conclusions.
CONCLUSION
We concluded that by engaging NET in release, tyramine prevented
norepinephrine re-uptake, and, through that, allowed influence of
presynaptic control to be demonstrated as differences in norep-
inephrine overflow to plasma. Tyramine therefore proved a new
and useful tool to study receptors involved in presynaptic con-
trol of release, in spite of that NET-mediated norepinephrine
release itself is not under presynaptic control. In addition, due
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to the fact that tyramine stimulated endogenous norepineph-
rine release, influence on a sympathetic cardiovascular response
could be studied simultaneously. The adrenal secretion of epi-
nephrine represented a physiological response to the stress induced
by the surgical procedure itself. Also this response was sensitive
to release control. We were therefore able to demonstrate that
peripheral α2AR limited both norepinephrine and epinephrine
release in WKYs, but failed to do so in SHRs. The same was
true for the α2AR control of TPR. These disorders in SHRs were
observed only when norepinephrine release was stimulated. The
α2AR malfunctions in SHRs was repaired by the agonist cloni-
dine, either through a direct stimulation of peripheral α2AR or
through its ability to reduce central sympathetic output. Sympa-
thetic hyperactivity is now generally accepted as a major player
in initiating and sustaining hypertension in SHRs and man. α2AR
auto-inhibition represents an important physiological mechanism
to lower adrenergic activity both in CNS and peripherally. The
present experiments provided a method by which the mecha-
nisms underlying the failing α2AR catecholamines release con-
trol in SHRs can be studied in vivo. A better understanding
of why their function is disturbed in SHRs, may improve our
understanding of the pathological mechanisms causing not only
spontaneous hypertension, but also other conditions involving
α2AR, such as diabetes type II and behavior and cognitive dis-
orders (Hunt et al., 1995; Crassous et al., 2007; Fagerholm et al.,
2011).
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